ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On June 1, 2017, OncoSec Medical Incorporated (the Company)
issued a press release regarding the Companys financial results
for the third quarter of the fiscal year ending July 31, 2017. A
copy of the Companys press release containing this information is
being furnished as Exhibit 99.1 to this Current Report.
The information in this Current Report, including Exhibit 99.1
furnished herewith, is being furnished and shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the Exchange Act), or otherwise subject to
the liabilities of that Section. The information in this Current
Report shall not be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such a filing to this Current Report.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
| Exhibit | Description | |
| 99.1 | OncoSec Medical Incorporated press release dated June 1, 2017 |
About ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS)
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses. ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS) Recent Trading Information
ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS) closed its last trading session up +0.06 at 1.13 with 87,472 shares trading hands.
